ATE127694T1 - Lebende impfstoffe. - Google Patents

Lebende impfstoffe.

Info

Publication number
ATE127694T1
ATE127694T1 AT90305819T AT90305819T ATE127694T1 AT E127694 T1 ATE127694 T1 AT E127694T1 AT 90305819 T AT90305819 T AT 90305819T AT 90305819 T AT90305819 T AT 90305819T AT E127694 T1 ATE127694 T1 AT E127694T1
Authority
AT
Austria
Prior art keywords
live vaccines
attenuating
bacteria
vaccines
concerned
Prior art date
Application number
AT90305819T
Other languages
English (en)
Inventor
Gordan Dougan
Steven Neville Chatfield
Christopher Francis Higgins
Charles James Dorman
Original Assignee
Wellcome Found
Royal Society
Lister Preventive Med
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found, Royal Society, Lister Preventive Med, Univ Dundee filed Critical Wellcome Found
Application granted granted Critical
Publication of ATE127694T1 publication Critical patent/ATE127694T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/826—Bacterial vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT90305819T 1989-05-30 1990-05-29 Lebende impfstoffe. ATE127694T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898912330A GB8912330D0 (en) 1989-05-30 1989-05-30 Live vaccines

Publications (1)

Publication Number Publication Date
ATE127694T1 true ATE127694T1 (de) 1995-09-15

Family

ID=10657547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90305819T ATE127694T1 (de) 1989-05-30 1990-05-29 Lebende impfstoffe.

Country Status (9)

Country Link
US (2) US5851519A (de)
EP (1) EP0400958B1 (de)
JP (1) JP3024982B2 (de)
AT (1) ATE127694T1 (de)
DE (1) DE69022290T2 (de)
DK (1) DK0400958T3 (de)
ES (1) ES2077028T3 (de)
GB (1) GB8912330D0 (de)
GR (1) GR3017535T3 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811105A (en) * 1987-12-23 1998-09-22 Glaxo Wellcome, Inc. Vaccines containing bacteria attenuated by mutations in two genes of the aromatic amino acid biosynthetic pathway
GB9007194D0 (en) * 1990-03-30 1990-05-30 Wellcome Found Live vaccines
JP3415145B2 (ja) * 1991-03-05 2003-06-09 ザ ウエルカム ファウンデーション リミテッド 弱毒化細菌における組換えタンパク質の発現
ATE174628T1 (de) * 1992-07-31 1999-01-15 Medeva Holdings Bv Expression rekombinanter fusionsproteine in attenuierten bakterien
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
WO1995004133A1 (en) * 1993-07-30 1995-02-09 The University Of North Carolina At Chapel Hill Production of gonorrheal pi proteins and vaccines in e. coli and salmonella
US6254874B1 (en) * 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
AUPN631395A0 (en) * 1995-11-02 1995-11-23 Commonwealth Scientific And Industrial Research Organisation Vaccine and biological vector(II)
EP0810283A3 (de) * 1996-05-31 1997-12-10 Akzo Nobel N.V. Lebende attenuierte RTX-produzierende Bakterien aus der Familie pasteurellaceae
ZA974809B (en) 1996-05-31 1998-01-23 Akzo Nobel Nv Live attenuated RTX-producing bacteria of the family pasteurellaceae.
ES2301181T3 (es) * 1997-08-21 2008-06-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas.
CN1253551C (zh) 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
GB9726233D0 (en) * 1997-12-11 1998-02-11 Medeva Europ Ltd Vaccines containing attenuated bacteria
US6905691B1 (en) 1997-12-11 2005-06-14 Celltech Pharma Europe Limited Vaccines containing attenuated bacteria
GB9806449D0 (en) 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
RU2140288C1 (ru) * 1998-04-09 1999-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ получения живой коревой вакцины
DE69935927T2 (de) * 1998-12-02 2008-01-10 University Of Maryland, Baltimore Plasmidstabilisierungssystem für die verabreichung von antigenen
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
EP1169465B1 (de) * 1998-12-04 2006-03-01 University Of Manitoba Zwei-schritte-verfahren zur impfung gegen chlamydia
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
NZ519477A (en) * 1999-12-23 2004-04-30 Microscience Ltd Attenuated microorganisms for the treatment of infection
US6872547B1 (en) 2000-10-11 2005-03-29 Washington University Functional balanced-lethal host-vector systems
JP4886122B2 (ja) * 2001-05-31 2012-02-29 日水製薬株式会社 腸炎ビブリオ検出用培地
WO2002102409A1 (en) * 2001-06-19 2002-12-27 Medical Research Council Inactivated mycobacterial ompatb and uses thereof
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
AUPR977601A0 (en) * 2001-12-28 2002-01-31 Delta Biotechnology Limited Defective entities and uses therefor
CA2526895A1 (en) * 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
US7357935B2 (en) 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
US7364745B2 (en) * 2004-02-06 2008-04-29 Virginia Tech Intellectual Properties, Inc. Development of a live, attenuated, recombinant vaccine for Brucellosis
GB2412259A (en) * 2004-03-16 2005-09-21 Wolfson Ltd A CMOS folded-cascode operational amplifier having low flicker noise
CN1276076C (zh) * 2004-12-14 2006-09-20 华东理工大学 一种鳗弧菌野生毒株的无标记基因缺失减毒突变株及其应用
FR2898276B1 (fr) * 2006-03-08 2008-07-25 Univ Claude Bernard Lyon Nouveaux vaccins destines au traitement ou a la prevention des infections par parasites de la famille des taenidae et en particulier du genre echinococcus
KR102730367B1 (ko) 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
MX2022006299A (es) 2019-11-25 2023-01-19 Univ Griffith Proteína inmunogénica contra una infección gonocócica.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB184086A (en) * 1921-09-16 1922-08-10 William Henry Taylor Improvements relating to endless conveyors
IL59663A (en) * 1980-03-19 1983-02-23 Univ Ramot Vaccines obtained from bacterial mutant strains of enterobacteriaceae and pseudomonaceae
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
DK189788D0 (da) * 1988-04-07 1988-04-07 Wolf Watz Hans Vaccine
ES2090129T3 (es) * 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.

Also Published As

Publication number Publication date
JP3024982B2 (ja) 2000-03-27
EP0400958B1 (de) 1995-09-13
JPH03117481A (ja) 1991-05-20
GB8912330D0 (en) 1989-07-12
DE69022290T2 (de) 1996-09-05
GR3017535T3 (en) 1995-12-31
DE69022290D1 (de) 1995-10-19
ES2077028T3 (es) 1995-11-16
EP0400958A2 (de) 1990-12-05
EP0400958A3 (de) 1991-09-18
US5851519A (en) 1998-12-22
DK0400958T3 (da) 1996-01-15
US5527529A (en) 1996-06-18

Similar Documents

Publication Publication Date Title
DK0400958T3 (da) Levende vacciner
BG44877A3 (bg) Метод за експресия на ген,кодиращ човешки имунен интерферон
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
PT80300A (de) Herstellung von polypeptiden mit human-gammainterferonaktivitat
ATE184193T1 (de) Verwendung von n-acylaminoalkoholen zur herstellung eines arzneimittels zur behandlung von mastzellerkrankungen
DE3776367D1 (de) Sterilisationsverfahren.
DE3681144D1 (de) Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren.
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE68912020D1 (de) N-2,3-Butadienyl-tri-aminoalkanderivate.
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE69333812D1 (de) Endo-Xyloglucan-Transferase
ATE62270T1 (de) Herstellung des e.coli-lt-benterotoxinunterteils.
DE69432856D1 (de) Zufuhr von genprodukten mittels mesangium-zellen
DK0406745T3 (da) Antibiotiske GE 2270 faktorer A1, A2, A3 og H
ATE78403T1 (de) Impfstoff gegen mastitis.
DK0451486T3 (da) Antibiotikum GE 2270 faktorer B1, B2, C1, C2, D1, D2, E og T
YU47473B (sh) Postupak za dobijanje vakcine protiv trovanja krvi živine escherichijom coli
DE68904131D1 (de) Schweinenierenzellkultur und ihre verwendung fuer die herstellung von vakzinen.
JPS6480298A (en) Production of human proapolipoprotein a-i-like protein
ATE48531T1 (de) Verfahren zum sterilisieren von rekombinantem mikroorganismus.
DE69032471D1 (de) Proteine mit onkostatin-m-aktivität und verfahren zu ihrer herstellung
SE8002898L (sv) Biologiskt aktiv substans och forfarande for framstellning derav
KR850700110A (ko) 백신 및 이의 제조방법
IT1276765B1 (it) Gene del cromosoma x umano e proteina codificata da detto gene.
ATE66611T1 (de) Verwendung biologisch aktiver copolymere zur herstellung eines arzneimittels zur stimulierung des wachstums von tieren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time